Tourmaline Bio (TRML) is hosting its Investor Day. Tourmaline today is announcing the over-enrollment of its Phase 2 TRANQUILITY trial, which evaluates quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Tourmaline expects to report topline data from this trial in the second quarter of 2025. Expansion of Cardiovascular Scientific Advisory Board, SAB, with two new appointments: Deepak L. Bhatt; Dipender Gill.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
Questions or Comments about the article? Write to editor@tipranks.com